<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Alnylam Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/alnylam-pharmaceuticals-inc</link>
<description>Latest news and press releases for Alnylam Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 16 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/alnylam-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835455878dffbe2df0e2845.webp</url>
<title>Alnylam Pharmaceuticals Inc</title>
<link>https://6ix.com/company/alnylam-pharmaceuticals-inc</link>
</image>
<item>
<title>Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results</title>
<link>https://6ix.com/company/alnylam-pharmaceuticals-inc/news/alnylam-to-webcast-conference-call-discussing-first-quarter-2026-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/alnylam-pharmaceuticals-inc/news/alnylam-to-webcast-conference-call-discussing-first-quarter-2026-financial-results</guid>
<pubDate>Thu, 16 Apr 2026 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report</description>
</item>
<item>
<title>New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management</title>
<link>https://6ix.com/company/alnylam-pharmaceuticals-inc/news/new-data-presented-at-acc26-further-support-benefits-of-vutrisiran-in-attr-cm-and-potential-of-zilebesiran-for-hypertension-management</link>
<guid isPermaLink="true">https://6ix.com/company/alnylam-pharmaceuticals-inc/news/new-data-presented-at-acc26-further-support-benefits-of-vutrisiran-in-attr-cm-and-potential-of-zilebesiran-for-hypertension-management</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>− Vutrisiran, which Silences Transthyretin at the Source, Shown to Improve Health-Related Quality-of-Life in Those with ATTR-CM, with Treatment Effects</description>
</item>
<item>
<title>Viz.ai Partners with Alnylam Pharmaceuticals to Advance Earlier Identification and Care Coordination in Cardiac Amyloidosis</title>
<link>https://6ix.com/company/alnylam-pharmaceuticals-inc/news/vizai-partners-with-alnylam-pharmaceuticals-to-advance-earlier-identification-and-care-coordination-in-cardiac-amyloidosis</link>
<guid isPermaLink="true">https://6ix.com/company/alnylam-pharmaceuticals-inc/news/vizai-partners-with-alnylam-pharmaceuticals-to-advance-earlier-identification-and-care-coordination-in-cardiac-amyloidosis</guid>
<pubDate>Tue, 24 Mar 2026 13:00:00 GMT</pubDate>
<description>SAN FRANCISCO, March 24, 2026--Viz.ai, the leader in AI-powered disease detection and care coordination, today announced a partnership with Alnylam Pharmaceuticals, the leading RNAi therapeutics company, to accelerate early identification and standardize diagnostic evaluation of patients with cardiac amyloidosis, a serious and underdiagnosed cause of heart failure.</description>
</item>
<item>
<title>Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association</title>
<link>https://6ix.com/company/alnylam-pharmaceuticals-inc/news/alnylam-advances-future-of-attr-cm-care-through-strategic-collaboration-with-vizai-and-support-for-the-american-heart-association</link>
<guid isPermaLink="true">https://6ix.com/company/alnylam-pharmaceuticals-inc/news/alnylam-advances-future-of-attr-cm-care-through-strategic-collaboration-with-vizai-and-support-for-the-american-heart-association</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>− Efforts Aimed at Facilitating Earlier Diagnosis, Coordinated Care, and Long-Term Patient Impact in ATTR-CM – − Alnylam to Host TTR Investor Webinar Today</description>
</item>
<item>
<title>Alnylam to Webcast TTR Investor Webinar</title>
<link>https://6ix.com/company/alnylam-pharmaceuticals-inc/news/alnylam-to-webcast-ttr-investor-webinar-4</link>
<guid isPermaLink="true">https://6ix.com/company/alnylam-pharmaceuticals-inc/news/alnylam-to-webcast-ttr-investor-webinar-4</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast</description>
</item>
<item>
<title>Helix Announces Multi-Year Agreement with Alnylam to Drive Precision Medicine Development</title>
<link>https://6ix.com/company/alnylam-pharmaceuticals-inc/news/helix-announces-multi-year-agreement-with-alnylam-to-drive-precision-medicine-development</link>
<guid isPermaLink="true">https://6ix.com/company/alnylam-pharmaceuticals-inc/news/helix-announces-multi-year-agreement-with-alnylam-to-drive-precision-medicine-development</guid>
<pubDate>Thu, 05 Mar 2026 14:05:00 GMT</pubDate>
<description>Helix, the leading enterprise genomics company, today announced a multi-year relationship with Alnylam, the leading RNAi therapeutics company. This agreement provides Alnylam access to Helix's continuously growing, deeply phenotyped GenoSphere™ cohorts that cover a wide range of disease areas.</description>
</item>
<item>
<title>Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics</title>
<link>https://6ix.com/company/alnylam-pharmaceuticals-inc/news/tenaya-therapeutics-enters-into-research-collaboration-with-alnylam-pharmaceuticals-to-identify-and-validate-novel-genetic-targets-for-cardiovascular-disease-therapeutics-30</link>
<guid isPermaLink="true">https://6ix.com/company/alnylam-pharmaceuticals-inc/news/tenaya-therapeutics-enters-into-research-collaboration-with-alnylam-pharmaceuticals-to-identify-and-validate-novel-genetic-targets-for-cardiovascular-disease-therapeutics-30</guid>
<pubDate>Thu, 05 Mar 2026 13:30:00 GMT</pubDate>
<description>Agreement Combines Tenaya’s Expertise in Identification and Validation ofGenetic Heart Disease Targets with Alnylam’s Ability to Deliver Transformational Therapeutics Tenaya to Receive Up to $10 Million in Upfront Payments in Addition to Research Funding and Milestone Payments of Up to $1.13 Billion SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potent</description>
</item>
<item>
<title>Protego Biopharma Appoints John M. Maraganore, Ph.D., to Board of Directors</title>
<link>https://6ix.com/company/alnylam-pharmaceuticals-inc/news/protego-biopharma-appoints-john-m-maraganore-phd-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/alnylam-pharmaceuticals-inc/news/protego-biopharma-appoints-john-m-maraganore-phd-to-board-of-directors</guid>
<pubDate>Tue, 03 Mar 2026 14:00:00 GMT</pubDate>
<description>Protego Biopharma, Inc., a clinical-stage biotechnology company dedicated to pioneering first-in-class small molecule therapeutics that reprogram protein folding to address systemic amyloid diseases and other protein misfolding disorders, today announced the appointment of John M. Maraganore, Ph.D., to its Board of Directors.</description>
</item>
<item>
<title>Alnylam Receives Positive Recommendation From Canada's Drug Agency (CDA) for the Public Reimbursement of AMVUTTRA® (vutrisiran injection), the First and Only RNAi Therapeutic for the Treatment of Cardiomyopathy in Adult Patients with ATTR Amyloidosis</title>
<link>https://6ix.com/company/alnylam-pharmaceuticals-inc/news/alnylam-receives-positive-recommendation-from-canadas-drug-agency-cda-for-the-public-reimbursement-of-amvuttrar-vutrisiran-injection-the-first-and-only-rnai-therapeutic-for-the-treatment-of-cardiomyopathy-in-adult-patients-with-attr-amyloidosis</link>
<guid isPermaLink="true">https://6ix.com/company/alnylam-pharmaceuticals-inc/news/alnylam-receives-positive-recommendation-from-canadas-drug-agency-cda-for-the-public-reimbursement-of-amvuttrar-vutrisiran-injection-the-first-and-only-rnai-therapeutic-for-the-treatment-of-cardiomyopathy-in-adult-patients-with-attr-amyloidosis</guid>
<pubDate>Mon, 02 Mar 2026 13:01:00 GMT</pubDate>
<description>Alnylam Canada ULC is pleased to announce it has received a positive recommendation from Canada's Drug Agency (CDA) for the public reimbursement of its RNAi therapeutic, AMVUTTRA®.1 In December 2025, AMVUTTRA® was authorized by Health Canada for the treatment of cardiomyopathy in adult patients with wild-type or hereditary transthyretin-mediated amyloidosis (wtATTR or hATTR amyloidosis). This is an expanded indication for AMVUTTRA®, which was originally authorized for sale in Canada in 2023 for</description>
</item>
<item>
<title>Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/alnylam-pharmaceuticals-inc/news/alnylam-to-webcast-presentation-at-td-cowen-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/alnylam-pharmaceuticals-inc/news/alnylam-to-webcast-presentation-at-td-cowen-46th-annual-health-care-conference</guid>
<pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will</description>
</item>
<item>
<title>Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress</title>
<link>https://6ix.com/company/alnylam-pharmaceuticals-inc/news/alnylam-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-highlights-recent-period-progress</link>
<guid isPermaLink="true">https://6ix.com/company/alnylam-pharmaceuticals-inc/news/alnylam-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-highlights-recent-period-progress</guid>
<pubDate>Thu, 12 Feb 2026 05:00:00 GMT</pubDate>
<description>− Achieved Fourth Quarter and Full Year 2025 Global Net Product Revenues of $995 Million and $2,987 Million, Respectively, Representing 121% and 81% Growth</description>
</item>
<item>
<title>Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/alnylam-pharmaceuticals-inc/news/alnylam-webcast-conference-call-discussing-fourth-quarter-and-full-year-2025</link>
<guid isPermaLink="true">https://6ix.com/company/alnylam-pharmaceuticals-inc/news/alnylam-webcast-conference-call-discussing-fourth-quarter-and-full-year-2025</guid>
<pubDate>Thu, 29 Jan 2026 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report</description>
</item>
<item>
<title>Adimab Reports Strong Partnering Year for 2025</title>
<link>https://6ix.com/company/alnylam-pharmaceuticals-inc/news/adimab-reports-strong-partnering-year-for-2025</link>
<guid isPermaLink="true">https://6ix.com/company/alnylam-pharmaceuticals-inc/news/adimab-reports-strong-partnering-year-for-2025</guid>
<pubDate>Mon, 12 Jan 2026 19:57:00 GMT</pubDate>
<description>Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that it entered into partnership agreements with 23 companies in 2025. In addition, Adimab achieved 50 technical and development milestones across numerous collaborations.</description>
</item>
<item>
<title>Alnylam Launches "Alnylam 2030" Strategy to Drive Next Era of Growth and Patient Impact</title>
<link>https://6ix.com/company/alnylam-pharmaceuticals-inc/news/alnylam-launches-alnylam-2030-strategy-to-drive-next-era-of-growth-and-patient-impact</link>
<guid isPermaLink="true">https://6ix.com/company/alnylam-pharmaceuticals-inc/news/alnylam-launches-alnylam-2030-strategy-to-drive-next-era-of-growth-and-patient-impact</guid>
<pubDate>Sun, 11 Jan 2026 22:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., January 11, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its new five-year strategy, "Alnylam 2030," focused on scaling the Company’s operations through achieving leadership in ATTR amyloidosis, driving long-term growth through sustainable innovation, and delivering exceptional financial results with discipline and agility. Alnylam also today reported preliminary* fourth quarter and full year 2025 global net product</description>
</item>
<item>
<title>Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact</title>
<link>https://6ix.com/company/alnylam-pharmaceuticals-inc/news/alnylam-launches-alnylam-2030-strategy-drive-next-era-growth-and-patient-impact-2026</link>
<guid isPermaLink="true">https://6ix.com/company/alnylam-pharmaceuticals-inc/news/alnylam-launches-alnylam-2030-strategy-drive-next-era-growth-and-patient-impact-2026</guid>
<pubDate>Sun, 11 Jan 2026 05:00:00 GMT</pubDate>
<description>− Full Year 2025 Preliminary* Net Product Revenues of $2,987 Million (81% Growth vs. 2024), Driven Primarily by Preliminary* Total TTR Revenues of $2,487</description>
</item>
<item>
<title>Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/alnylam-pharmaceuticals-inc/news/alnylam-webcast-presentation-44th-annual-jp-morgan-healthcare-conference-2026-01-05</link>
<guid isPermaLink="true">https://6ix.com/company/alnylam-pharmaceuticals-inc/news/alnylam-webcast-presentation-44th-annual-jp-morgan-healthcare-conference-2026-01-05</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will</description>
</item>
<item>
<title>PeptiDream and Alnylam Announce Achievement of Key Milestone in siRNA Conjugate Discovery Collaboration Demonstrating Peptide-Ligand Mediated Targeted siRNA Delivery to Specific Extrahepatic Tissues</title>
<link>https://6ix.com/company/alnylam-pharmaceuticals-inc/news/peptidream-and-alnylam-announce-achievement-of-key-milestone-in-sirna-conjugate-discovery-collaboration-demonstrating-peptide-ligand-mediated-targeted-sirna-delivery-to-specific-extrahepatic-tissues</link>
<guid isPermaLink="true">https://6ix.com/company/alnylam-pharmaceuticals-inc/news/peptidream-and-alnylam-announce-achievement-of-key-milestone-in-sirna-conjugate-discovery-collaboration-demonstrating-peptide-ligand-mediated-targeted-sirna-delivery-to-specific-extrahepatic-tissues</guid>
<pubDate>Thu, 18 Dec 2025 12:00:00 GMT</pubDate>
<description>KAWASAKI, Japan, December 18, 2025--A key step to deliver RNAi therapeutics to diverse cell types and tissues beyond the liver from the collaboration of PeptiDream and Alnylam from 2021.</description>
</item>
<item>
<title>Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics</title>
<link>https://6ix.com/company/alnylam-pharmaceuticals-inc/news/alnylam-invest-250-million-add-enzymatic-ligation-platform-us-manufacturing-facility</link>
<guid isPermaLink="true">https://6ix.com/company/alnylam-pharmaceuticals-inc/news/alnylam-invest-250-million-add-enzymatic-ligation-platform-us-manufacturing-facility</guid>
<pubDate>Wed, 17 Dec 2025 05:00:00 GMT</pubDate>
<description>New platform is expected to substantially increase manufacturing capacity and lower production costs, enabling investment in expanding pipeline FDA has</description>
</item>
<item>
<title>Alnylam Announces Health Canada Approval of AMVUTTRA® (vutrisiran), the First and Only RNAi Therapeutic for the Treatment of Cardiomyopathy in Adult Patients with ATTR Amyloidosis</title>
<link>https://6ix.com/company/alnylam-pharmaceuticals-inc/news/alnylam-announces-health-canada-approval-of-amvuttrar-vutrisiran-the-first-and-only-rnai-therapeutic-for-the-treatment-of-cardiomyopathy-in-adult-patients-with-attr-amyloidosis</link>
<guid isPermaLink="true">https://6ix.com/company/alnylam-pharmaceuticals-inc/news/alnylam-announces-health-canada-approval-of-amvuttrar-vutrisiran-the-first-and-only-rnai-therapeutic-for-the-treatment-of-cardiomyopathy-in-adult-patients-with-attr-amyloidosis</guid>
<pubDate>Tue, 16 Dec 2025 13:01:00 GMT</pubDate>
<description>Alnylam Canada ULC is pleased to announce that Health Canada has issued a Notice of Compliance (NOC) authorizing AMVUTTRA® (vutrisiran) for the treatment of cardiomyopathy in adult patients with wild-type or hereditary transthyretin-mediated amyloidosis (wtATTR or hATTR amyloidosis).1 The approval broadens the indication for AMVUTTRA®, which now becomes the first and only RNAi therapeutic authorized by Health Canada for the treatment of both the cardiomyopathy manifestations of TTR amyloidosis a</description>
</item>
<item>
<title>Annual Changes to the Nasdaq-100 Index®</title>
<link>https://6ix.com/company/alnylam-pharmaceuticals-inc/news/annual-changes-to-the-nasdaq-100-indexr</link>
<guid isPermaLink="true">https://6ix.com/company/alnylam-pharmaceuticals-inc/news/annual-changes-to-the-nasdaq-100-indexr</guid>
<pubDate>Sat, 13 Dec 2025 01:00:00 GMT</pubDate>
<description>NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq-100 Index® (NDX®), which will become effective prior to market open on Monday, December 22, 2025. The following six companies will be added to the Index: Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), Ferrovial SE (Nasdaq: FER), Insmed Incorporated (Nasdaq: INSM), Monolithic Power Systems, Inc. (Nasdaq: MPWR), Seagate Technology Holdings plc (Nasdaq: STX), Weste</description>
</item>
</channel>
</rss>